Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00820300 · ClinicalTrials.gov registry record · Phase 2

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

A Phase 2 study, sponsored by Mati Therapeutics.

Completed
Registry status
Phase 2
Development phase
113
Enrollment target

NCT00820300 is a Phase 2 study that has completed, run by Mati Therapeutics. The registered enrollment target is 113 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00820300, a Phase 2 study, has completed, sponsored by Mati Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
113 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the Punctal Plug Delivery System is safe and effective in controlling intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Interventions

  • DRUG Latanoprost-PPDS

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2009-01
Est. Completion 2009-12
Phase Phase 2

Sponsor

Mati Therapeutics

12 total trials

What the Registry Record Tells You About NCT00820300

The ClinicalTrials.gov registry entry for NCT00820300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mati Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Latanoprost-PPDS is the first listed.

NCT00820300 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00820300 about?

NCT00820300 is a clinical study titled "A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma". The purpose of this study is to determine if the Punctal Plug Delivery System is safe and effective in controlling intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

What is the current status of trial NCT00820300?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2009-01. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00820300?

The interventions under investigation include: Latanoprost-PPDS (DRUG).

Who is sponsoring clinical trial NCT00820300?

This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.